-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH/EHA Joint Symposium

Program: General Sessions
Sunday, December 6, 2015: 12:30 PM-1:30 PM
Hall D, Level 2 (Orange County Convention Center)

Lecture Title:
Impact of Genomes: How Well Are We Incorporating the Assessments of Actionable Results?

David A. Williams, MD, President, American Society of Hematology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School and Anthony R Green, PhD, FRCP, FRCPath, President, European Hematology Association, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute

No relevant conflicts of interest to declare.

Genomic sequencing of tumors has contributed to new understanding of transformation biology and has also identified key drivers of disease that represent new therapeutic targets. The genomic landscape has raised important questions and challenges related to validation of targets, operationalization of the process by which mutation identification leads to appropriate therapeutic interventions, and the impact of highly personalized approaches on clinical trial development and implementation. The 2015 ASH/EHA Joint Symposium will provide two experts’ perspectives on how far the field has advanced in using genomic data to guide leukemia therapies in both the United States and in Europe.

This symposium is co-sponsored by ASH and the European Hematology Association (EHA) and will continue to focus on issues that two societies have identified as important to hematologists from countries around the world.

Ross L. Levine, MD

Memorial Sloan Kettering Cancer Center, New York, NY

Torsten Haferlach, MD

MLL Munich Leukemia Laboratory, Munich, Germany

See more of: General Sessions